| | | 统计截止日 区间股价涨跌幅 股东户数 增减 增减比例 户均持股市值（元） | | | 户均持股数(股) | | --- | --- | --- | --- | --- | --- | | 2025-06-30 | 2.51% | 30095 -218 | -0.72% | 9.51万 | 9485.17 | | 2025-03-31 | -0.30% | 30313 -1048 | -3.34% | 9.30万 | 9416.96 | | 2024-12-31 | 3.66% | 31361 3244 | 11.54% | 9.02万 | 9102.27 | | 2024-09-30 | 17.88% | 28117 -1757 | -5.88% | 9.71万 | 1.02万 | 证券之星消息，近日联环药业披露，截至2025年6月30日公司股东户数为3.01万户，较3月31日减少218.0 户，减幅为0.72%。户均持股数量由上期的9417.0股增加至9485.0股，户均持股市值为9.51万元。 在化学制药行业个股中，联环药业股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东 户数为 ...

Core Points - The Chinese government emphasizes that modernity is fundamentally linked to public health, with a focus on affordable and essential medications for the population [1] - The market regulatory authorities have intensified anti-monopoly enforcement in the pharmaceutical sector, resulting in significant price reductions for essential drugs [2][3] - Recent anti-monopoly cases have restored market competition and reduced both patient medication costs and insurance expenditures [3][4] Summary by Sections Anti-Monopoly Enforcement - The market regulatory authorities have taken strong actions against pharmaceutical monopolies, with penalties totaling 6.23 billion yuan in the first half of the year [4] - Specific cases include the price manipulation of dexamethasone phosphate sodium, where the price surged from 8,000 yuan per kilogram to 13,000 yuan, leading to a 282-fold increase in the injection price [2][3] - The authorities have implemented a "punishment to individuals" approach, holding both companies and responsible individuals accountable for anti-competitive practices [5] Market Impact - The crackdown on monopolistic practices has led to a nearly 94% price reduction for dexamethasone phosphate sodium injection, from 7.2 yuan to 0.45 yuan [2][3] - The enforcement actions have also addressed other critical drugs, ensuring their availability and affordability for patients [3][4] Regulatory Framework - The market regulatory authorities are developing clearer anti-monopoly guidelines for the pharmaceutical sector, with a focus on enhancing compliance and preventing future violations [6][7] - The shift from punitive measures to proactive compliance strategies aims to foster a competitive environment that benefits public health [6][7] Industry Response - Pharmaceutical companies are increasingly recognizing the importance of compliance with anti-monopoly regulations as essential for their survival and competitiveness [7] - Training programs are being implemented to enhance awareness and understanding of anti-monopoly laws among industry professionals [7]

Core Points - The document outlines the rules for the board of directors of Jiangsu Lianhuan Pharmaceutical Co., Ltd., aiming to standardize meeting procedures and decision-making processes [2][3][19] Group 1: Board Structure and Meetings - The board consists of 9 directors, including 3 independent directors and 1 employee representative, with the chairman and vice-chairman also included [3][4] - Regular meetings must be held at least twice a year, while special meetings can be called under specific circumstances [4][5] - The board secretary is responsible for daily affairs and must ensure that meeting notifications are sent out in a timely manner [3][9] Group 2: Meeting Procedures - Meeting notifications for regular and special meetings must be sent out 10 days and 5 days in advance, respectively [9][10] - A quorum requires the presence of more than half of the directors, and the meeting can be conducted in person or through electronic means [11][14] - Decisions require a majority vote from the directors present, with specific rules for abstentions and conflicts of interest [19][15] Group 3: Documentation and Record-Keeping - The board secretary must maintain detailed records of meetings, including attendance, proposals, and voting results [25][27] - Meeting records must be signed by attending directors, and any dissenting opinions should be documented [17][18] - All meeting documentation must be preserved for at least ten years [30]

Core Points - The document outlines the system for appointing directors, supervisors, and senior executives in subsidiaries of Jiangsu Lianhuan Pharmaceutical Co., Ltd to strengthen management and protect the interests of the parent company [1][2] - The system is established in accordance with relevant laws, regulations, and internal control norms [1] Group 1: General Provisions - The system aims to enhance the management and control of subsidiaries by the parent company [1] - It defines the roles of appointed directors, supervisors, and senior executives as representatives of the parent company in subsidiaries [1] - The subsidiaries referred to include wholly-owned and controlled subsidiaries of the parent company [1] Group 2: Qualifications for Appointed Personnel - Appointed personnel must meet the qualifications set forth in the Company Law and the parent company's articles of association [2] - They should possess professional qualifications and experience of at least two years in similar positions [2] - Health and energy levels sufficient to fulfill their duties are also required [2] Group 3: Appointment and Dismissal Procedures - The appointment and dismissal procedures must comply with the collective decision-making system of the company [3] - The parent company's general manager, in collaboration with the HR department, recommends candidates for appointment [3] - The parent company may also utilize public recruitment to identify candidates for these positions [3] Group 4: Performance Evaluation and Compensation - The HR department of the parent company is responsible for evaluating the performance of appointed personnel [4] - Annual performance reports must be submitted by the appointed personnel to the HR department [4] - Compensation is linked to performance evaluations, with proposals submitted for approval by the parent company's management [4] Group 5: Legal Compliance and Responsibilities - Appointed personnel are required to comply with the Company Law and other relevant regulations [5] - The parent company retains the right to seek compensation for losses caused by negligence or misconduct of appointed personnel [5] - The system also applies to the appointment of personnel in affiliated subsidiaries, subject to actual circumstances [5]

Core Viewpoint - The management measures for the use of raised funds by Jiangsu Lianhuan Pharmaceutical Co., Ltd. aim to standardize the usage and management of raised funds, enhance their effectiveness, and protect investors' rights [1]. Group 1: General Principles - The purpose of the management measures is to regulate the use and management of raised funds, improve their effectiveness, and protect investors' rights based on relevant laws and regulations [1]. - The term "raised funds" refers to funds raised through public and non-public securities issuance, excluding funds raised for equity incentive plans [1]. - "Excess raised funds" refers to the portion of actual net raised funds that exceeds the planned amount [1]. Group 2: Fund Storage - Raised funds must be stored in a special account approved by the board of directors, and cannot be used for non-raised fund purposes [4]. - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank within one month of the funds being received [4][5]. - The agreement must include details such as the account number, project details, and monthly bank statements [5]. Group 3: Fund Usage - The company must adhere to specific requirements when using raised funds, including clear regulations on application, approval, and disclosure procedures [11]. - Funds should primarily be used for main business operations and cannot be used for financial investments or to benefit related parties improperly [13]. - Any changes in the use of raised funds must be approved by the board and disclosed to shareholders [24][25]. Group 4: Supervision and Reporting - The company must maintain accurate records of fund usage and undergo quarterly internal audits [16]. - The board is required to conduct a comprehensive review of project progress and fund usage every six months, issuing a special report [32]. - Independent directors and the audit committee must continuously monitor the management and usage of raised funds [33]. Group 5: Excess Funds Management - Excess funds can be used for permanent working capital or repaying bank loans, with specific limits on the amount used [10][11]. - Any use of excess funds must be approved by the board and disclosed to shareholders, including the necessity and detailed plans for such use [11].

Core Viewpoint - The article outlines the "Three Major and One Large" collective decision-making approval system of Jiangsu Lianhuan Pharmaceutical Co., Ltd, aimed at standardizing decision-making behavior, enhancing decision quality, and preventing risks and operational errors [1][2]. Group 1: Major Decision Matters - Major decision matters include significant strategic management issues such as development direction, operational policies, and long-term planning, as well as asset disposal, profit distribution, and high-risk operations [2]. - These decisions must be made by the Party Committee, Shareholders' Meeting, Board of Directors, General Manager's Office, or Workers' Representative Assembly [2]. Group 2: Important Personnel Appointments - Important personnel appointments involve the selection and dismissal of middle and senior management, as well as the delegation or replacement of shareholder representatives in subsidiaries [3]. - It also includes significant rewards and punishments related to management personnel [3]. Group 3: Major Project Arrangements - Major project arrangements refer to projects that significantly impact the company's asset scale, capital structure, resource allocation, and profitability [4]. - Projects with estimated contract values exceeding 4 million RMB for construction, 2 million RMB for major material procurement, and 1 million RMB for service procurement must follow bidding regulations [4]. Group 4: Large Amounts of Fund Operations - Large amounts of fund operations include significant budgeted and non-budgeted fund usage, as well as major donations and sponsorships [4]. - Any fund usage exceeding 3 million RMB must be reported to the Party Committee [4]. Group 5: Decision-Making Procedures - The decision-making process for "Three Major and One Large" matters includes pre-meeting research, collective discussion, and formal voting [7]. - Decisions must be made collectively, and no individual can unilaterally change the collective decision [12]. Group 6: Supervision and Accountability - The company’s Party Secretary, Chairman, and General Manager are the main responsible persons for implementing the decision-making system [18]. - Violations of laws or decision-making rules that result in losses will hold the main responsible person accountable [19]. Group 7: Reporting and Compliance - The implementation of the decision-making system is crucial for preventing corruption and ensuring lawful, scientific, and democratic decision-making [24]. - The company’s disciplinary committee is responsible for monitoring compliance and reporting any violations [26].

General Principles - The purpose of the system is to enhance the governance level of Jiangsu Lianhuan Pharmaceutical Co., Ltd. and to standardize the appointment, performance, and training of the board secretary [1] - The board secretary is a senior management personnel responsible to the company and the board, and must perform duties faithfully and diligently [1] - The board secretary serves as the designated liaison between the company and the Shanghai Stock Exchange, handling information disclosure, corporate governance, and equity management [1] Appointment - The company must appoint a board secretary within three months after the initial public offering or within three months after the previous secretary's departure [2] - Candidates for the board secretary must possess good professional ethics, necessary financial, management, and legal knowledge, relevant work experience, and a qualification certificate recognized by the Shanghai Stock Exchange [2] Disqualification - Individuals with certain disqualifying conditions, such as being banned from the securities market or having received public reprimands from the exchange, cannot serve as board secretaries [2] Dismissal - The company must have sufficient reasons for dismissing a board secretary and cannot dismiss without cause [3] - If a board secretary meets any disqualifying conditions, the company must dismiss them within one month of the occurrence [3] Responsibilities - The board secretary is responsible for managing information disclosure, including external communication, developing disclosure management systems, and ensuring compliance with disclosure obligations [5] - The board secretary assists in strengthening corporate governance mechanisms and managing investor relations [5][6] - The board secretary is also responsible for managing equity matters, including maintaining shareholder records and ensuring compliance with stock trading regulations [5] Training - Candidates for the board secretary position must undergo qualification training and obtain a certificate, with ongoing training required every two years [9] - Training topics include information disclosure, corporate governance, investor relations management, and the rights and obligations of the board secretary [9] Penalties - Serious violations of the management regulations may result in penalties from the Shanghai Stock Exchange, including public reprimands and disqualification from serving as a board secretary [11][12] Legal Responsibilities - The board secretary is subject to legal responsibilities for violations of laws, regulations, and company rules, which may lead to accountability [11]

江苏联环药业股份有限公司 董事、高级管理人员所持本公司股份及其变动管理办法 第一章 总则 第一条 为加强公司董事、高级管理人员（以下简称"高管"）所持本公司 股份及其变动的管理，根据《公司法》《证券法》《上市公司股东减持股份管理 暂行办法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》、 《上海证券交易所上市公司自律监管指引第 8 号——股份变动管理》、《上海证 券交易所上市公司自律监管指引第 8 号——股份变动管理》等相关法律、法规及 规范性文件的规定，结合公司实际情况，特制定本办法。 第二条 本办法适用于本公司董事、高管以及本办法第十四条规定的自然人、 法人或其他组织所持本公司股票及其变动的管理。 第三条 公司董事、高管在买卖本公司股票及其衍生品种前，应知悉《公司 法》、《证券法》等法律法规关于内幕交易、操纵市场等禁止行为的规定，不得 进行违法违规交易。 第四条 公司董事、高管所持有的本公司股份，是指登记在其名下和利用他 人账户持有的所有本公司股份。公司董事、高级管理人员从事融资融券交易时， 其所持本公司股份还包括记载在其信用账户内的本公司股份。 第五条 公司董事、高管可以通过上海证券交易所 ...

第二条 独立董事在上市公司年报的编制和披露过程中，应当切实履行独立 董事的责任和义务，勤勉尽责。 独立董事应认真学习和贯彻执行中国证监会发布的《上市公司独立董事管理 办法》、《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》、 《上市公司信息披露管理办法》和《公开发行证券的公司信息披露内容与格 式准则第 2 号——年度报告的内容与格式》以及本公司《公司信息披露事务管理 制度》。 第三条 公司管理层应在每个会计年度结束后 30 日内向每位独立董事全面 汇报公司本年度的生产经营情况和重大事项的进展情况，同时，公司应安排每位 独立董事进行实地考察。 上述事项应有书面记录，必要的文件应有当事人签字。 第四条 公司财务负责人应在为公司提供年报审计的注册会计师（以下简称 "年审注册会计师"）进场审计前向每位独立董事书面提交本年度审计工作安排 及其它相关资料。 江苏联环药业股份有限公司 独立董事年报工作制度 第一条 为明确独立董事在年报工作中的职责，进一步提高本公司信息披露 的质量，以保证本公司信息披露的真实、准确、完整、及时和公平，根据《上市 公司独立董事管理办法》等法律法规的规定，特制订本制度。 ...

江苏联环药业股份有限公司 防止控股股东、实际控制人及其他关联方占用公司资金管理制度 第一章 总则 第一条 为了进一步加强和规范江苏联环药业股份有限公司（以下简称 "公司"）的资金管理，防止和杜绝控股股东、实际控制人及关联方占用公司资 金行为的发生，保护公司、股东和其他利益相关人的合法权益，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、中国证监会《上市公司监管指引 第 8 号——上市公司资金往来、对外担保的监管要求》、《上海证券交易所股票 上市规则》及公司《章程》的有关规定，结合公司实际，制定本制度。 第二条 本制度适用于公司控股股东、实际控制人及关联方与公司间的资金管 理。公司控股股东、实际控制人及关联方与纳入合并会计报表范围的子公司之间 的资金往来适用本制度。 第三条 本制度所称"占用上市公司资金"（以下称"资金占用"），包括： 经营性资金占用和非经营性资金占用两种情况。 经营性资金占用，是指公司控股股东、实际控制人及关联方通过采购、销售等 生产经营环节的关联交易所产生的资金占用。 非经营性资金占用，是指公司为控股股东、实际控制人及关联方垫付工资、福 利、保险、广告等费用和其他支出，代控股股东、 ...